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whe past 2 decades have witnessed an explosion of basic and
linical research in atrial fibrillation (AF), and the pharma-
ologic and nonpharmacologic therapeutic options have
mproved tremendously (1). To provide clinicians with a
etter understanding of how to approach the management
f patients with AF, the American College of Cardiology,
merican Heart Association, and European Society of
ardiology published a comprehensive guidelines document
2). Restoration and maintenance of sinus rhythm are
ecommended for individuals with symptomatic AF in
hom the clinician thinks a rhythm- rather than rate-
ontrol strategy is most appropriate. The guidelines also
rovided an algorithm for maintenance of sinus rhythm that
tated clearly “selection of an appropriate agent is based first
n safety” and that catheter ablation was a reasonable
lternative to drugs in a variety of patient subgroups (2).
See page 2308
he Heart Rhythm Society subsequently published an AF
blation consensus document that stated “the primary jus-
ification for an AF ablation procedure . . . is the presence of
ymptomatic AF, with a goal of improving a patient’s
uality of life” (3). At present, no large prospective, ran-
omized trial has demonstrated a mortality benefit or stroke
eduction with rhythm-control over rate-control strategy in
he more elderly populations studied. At least for these
atients, it seems reasonable to choose a rhythm-control
trategy specifically when reduction of AF symptoms is
esired, and rate control is neither effective nor considered
ppropriate for that patient. Our personal bias is to select a
hythm-control strategy initially for the younger patients
ot well represented in the rhythm/rate strategy trials. In
he end, what we all want for our patients is a better quality
f life (QoL).
Wokhlu et al. (4) from the Mayo Clinic address this
mportant issue of QoL after catheter ablation of AF in this
ssue of the Journal. Of 502 patients undergoing ablation for
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From The Care Group, Indianapolis, Indiana. Dr. Prystowsky has served as ar
onsultant for Stereotaxis, Sanofi-Aventis, and Boehringer-Ingelheim and on the
oard of Directors of Stereotaxis and CardioNet.F, 323 (46% with paroxysmal AF) had a 2-year follow-up
hat included QoL data. The ablation methods changed
ver time and included pulmonary vein isolation in 22% of
atients and wide area circumferential ablation with addi-
ional linear lesions in 78% of patients; all underwent
avotricuspid isthmus ablation. QoL instruments included
he Medical Outcomes Study Short Form 36 (SF-36), and
ne developed at the Mayo Clinic, the Mayo AF-Specific
ymptom Inventory. Definitions for ablation outcomes
ere: 1) AF elimination (72% of patients)—arrhythmia free
ithout antiarrhythmic drugs at least 6 months before
valuation; 2) AF control with antiarrhythmic drugs (15%
f patients)—sinus rhythm requiring antiarrhythmic drugs
t least 6 months before evaluation; and 3) no AF control
ven with drugs (15% of patients).
Using the SF-36, both the physical and mental QoL
cores improved in patients after ablation. Surprisingly,
oL improvement did not seem to differ for the ablation
fficacy subgroups, with patients who had no AF recur-
ences having results similar to those not controlled even
ith drugs. A difference was noted using the Mayo AF-
pecific Symptom Inventory, and here the ablation out-
omes influenced the symptom results, and patients with
limination of AF fared better than those with recurrent
F. Although this seems to make sense, caution is advised
ith this analysis because it was only used in a smaller
ubgroup of patients and will require testing in a larger and
roader population of post-ablation patients. Specific fac-
ors that negatively affected QoL after ablation were obesity,
ontinued warfarin use, and higher baseline SF-36 scores.
he authors opine that the limited QoL improvement in
bese patients relates to diminished underlying functional
apacity, which may be correct, but this is an important
ssue that requires more investigation. If such patients are
ot likely to have a better QoL after ablation, even with no
F recurrence, then why should they undergo the risks of
he procedure? We caution any such conclusions along these
ines, but suggest that investigators look into this issue. The
egative effect on QoL with continued warfarin use is no
urprise; in fact, many patients request an ablation merely to
get off warfarin.” That said, until more safety data are
btained, patients at high risk of stroke should continue
arfarin therapy post-ablation even with no obvious AF
ecurrence (2,3). Perhaps newer anticoagulants will be better
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All’s Well That Ends Well, or Is It? May 25, 2010:2317–8olerated by patients (5). Last, it seems obvious that patients
ho had more favorable SF-36 scores at baseline would
erive less benefit after ablation.
Ablation is a second-line therapy for AF when antiar-
hythmic medications fail, as directed by the American
ollege of Cardiology, American Heart Association, and
uropean Society of Cardiology management guidelines
2). Second line does not mean second rate, and that has
ften been misunderstood. As a committee member
E.N.P.), the thought was to direct physicians to therapeutic
hoices that were the safest for the patient considering many
ariables, particularly underlying heart disease. Amiodarone
as consistently outperformed other antiarrhythmic agents
or maintenance of sinus rhythm, but it has many significant
nd potentially dangerous side effects and thus was relegated
o second-line use for most patient subgroups (2,6). Cath-
ter ablation is very effective for maintenance of sinus
hythm and typically is better than drug therapy when
rospectively tested in clinical trials (7). Wokhlu et al. (4)
elate major complications in 43 of their patients undergo-
ng catheter ablation for AF, and these are very experienced
blators. It is difficult to imagine a similar high rate of major
omplications in patients with no or minimal heart disease
ho are given a drug such as flecainide or even dronedarone
6). Thus, we still think it is reasonable to choose a drug
efore ablation for most patients with AF. There are
xceptions to this rule, including patients whose only drug
hoice is amiodarone, those who would require a pacemaker
f a drug was given, and, of course, a patient who simply
oes not want to take a drug.
Is it true that “all’s well that ends well,” at least for
atheter ablation of AF? The current data show us that QoL
s improved post-ablation for all categories of efficacy, even
o efficacy! So, by Shakespeare’s axiom, then all is well. But,
e know all is not well, and this means that we need to
eassess either how we assess QoL measures or determine
hether there are some unexplained mechanisms for symp-
om improvements with ablation of wide areas of left atrial
issue that do not correlate with AF recurrence. We have
ondered whether atrial sensory inputs are damaged or
ltered during ablation and how this might affect symptoms
f recurrent AF. Many of us have seen patients in our office
ho report feeling great ever since their ablation, and we
onder how we are going to break the news to them that
heir electrocardiogram demonstrates AF! It is well reported
hat silent AF occurs after ablation, even at times more lrequently than symptomatic episodes (3). Is this a mani-
estation of simply more intense monitoring, or have neural
nputs of the atria been altered?
We surely need to find a better way to quantify QoL for
atients with AF, at baseline and after pharmacologic or
onpharmacologic interventions. What exactly is QoL to
atients? It likely parallels how they view life in general and
s a measure of the degree of happiness that has been met or
ow fully their expectations have been realized. Perhaps we
hould take a lesson from the 1980 Carter-Reagan presi-
ential debate when Governor Reagan asked the American
eople “Are you better off than you were four years ago?”
e strongly suggest a better metric be developed, whether
he symptom index, Mayo AF-Specific Symptom Inven-
ory, used at the Mayo Clinic, or a new one, before
mbarking on prospective studies aimed at defining AF
herapies that improve QoL. We do not think that a failed
blation that yields a better QoL score is a success or a
esired end point.
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he Care Group, 8333 Naab Road, Indianapolis, Indiana 46032.
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